GLYX-13 TFA is a peptide-based compound that acts as an NMDA receptor modulator, specifically targeting the glycine site on the receptor complex. Its primary application lies in the field of neuroscience and psychiatric research, particularly in the development of fast-acting antidepressant therapies. Unlike traditional antidepressants that may take weeks to show effects, GLYX-13 TFA has demonstrated rapid onset of action in preclinical studies, improving depressive-like symptoms within hours and with sustained effects after a single dose. It has also shown potential in enhancing synaptic plasticity and cognitive function, making it a candidate for research in neurodegenerative disorders and cognitive impairments. Due to its ability to modulate glutamatergic signaling without causing the psychotomimetic side effects associated with other NMDA-targeting drugs, it is considered a promising scaffold for safer neuropsychiatric therapeutics. Research applications include use in animal models of depression, anxiety, and schizophrenia to evaluate behavioral and neurochemical outcomes.